Llwytho...
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relaps...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ther Adv Hematol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970705/ https://ncbi.nlm.nih.gov/pubmed/33796237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620721989588 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|